SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells

SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells

Drug: Melphalan
Intravenous melphalan (to be given in conjunction with the other listed drugs).Drug: BCNU
Intravenous BCNU (to be given in conjunction with the other listed drugs).
Other Name: Carmustine
Drug: Vitamin B12B
Intravenous vitamin B12b (to be given in conjunction with the other listed drugs).
Other Name: Hydroxocobalamin
Drug: Vitamin C
Intravenous vitamin C (to be given in conjunction with the other listed drugs).
Other Name: Ascorbic acid, sodium ascorbate
Drug: Ethanol
Intravenous ethanol (to be given in conjunction with the other listed drugs).
Device: Autologous Hematopoietic Stem Cells
After each cycle of chemotherapy, participants will receive an autologous hematopoietic stem cell infusion.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 26, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments